Fexinidazole
Treatment for African trypanosomiasis
Typical Dosage: 1200 mg/day for 4 days, then 600 mg/day for 6 days (adults)
Effectiveness
95%
Safety Score
65%
Clinical Trials
10
Participants
700
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
1200 mg/day for 4 days, then 600 mg/day for 6 days (adults)
Time to Effect
Within 2-4 weeks post-treatment
Treatment Duration
10 days
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$500
Side Effect Mgmt:$160
Total Annual:$860
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
5
Outcome-Based Costs
Cost per Responder
$905
Cost per Remission
$956
Comparison vs NECT
Cost Difference
$-943/year
Less expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
8 completed trials for Fexinidazole in African trypanosomiasis
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
NCT02571062COMPLETEDPHASE1
30 participants
INTERVENTIONAL
Rennes, France
Started: Mar 1, 2015
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
NCT03025789COMPLETEDPHASE3
174 participants
INTERVENTIONAL
Mbuji-Mayi, Democratic Republic of the Congo +7 more
Started: Nov 10, 2016
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole
NCT00982904COMPLETEDPHASE1
108 participants
INTERVENTIONAL
Paris, France
Started: Sep 1, 2009
Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study
NCT02169557COMPLETEDPHASE2, PHASE3
230 participants
INTERVENTIONAL
Kinshasa, Democratic Republic of the Congo
Started: Apr 30, 2014
Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study
NCT02184689COMPLETEDPHASE2, PHASE3
125 participants
INTERVENTIONAL
Kinshasa, Democratic Republic of the Congo
Started: May 3, 2014
Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense
NCT03974178COMPLETEDPHASE2, PHASE3
45 participants
INTERVENTIONAL
Rumphi, Malawi +1 more
Started: Sep 29, 2019
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
NCT01685827COMPLETEDPHASE2, PHASE3
394 participants
INTERVENTIONAL
Batangafo, Central African Republic +9 more
Started: Oct 1, 2012
Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions
NCT01340157COMPLETEDPHASE1
12 participants
INTERVENTIONAL
Paris, France
Started: Feb 1, 2011